R&G PharmaStudies Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
David Wu
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | less than a year |
Recent management updates
Recent updates
R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings
Nov 06
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20
Jul 01Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?
Jun 06Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings
Apr 29CEO
David Wu (63 yo)
no data
Tenure
CN¥1,436,800
Compensation
Mr. Wu Jie, also known as David, MBA serves as Chairman and General manager of R&G PharmaStudies Co., Ltd. He served as General Manager and Director of Tianfa Petroleum Co., Ltd.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | no data | CN¥1.44m | no data | |
| COO, Senior VP & Director | no data | CN¥680.80k | no data | |
| Deputy GM & Director | no data | CN¥832.00k | no data | |
| Senior VP | no data | CN¥567.50k | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | no data | no data | 12.15% CN¥ 608.9m | |
| Supervisor | no data | no data | no data | |
| Supervisory Board Chairman | no data | no data | no data | |
| Supervisor | no data | no data | no data | |
| Director | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
0.6yrs
Average Tenure
55yo
Average Age
Experienced Board: 301333's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 19:35 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
R&G PharmaStudies Co., Ltd. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hao Wu | Chasing Securities |
| Jin Zhang | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |